Merotocin - Ferring pharmaceuticals
Alternative Names: FE-202767Latest Information Update: 27 Jan 2023
Price :
$50 *
At a glance
- Originator Ferring Pharmaceuticals
- Class Hormones; Oxytocics
- Mechanism of Action Oxytocin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Lactation failure
Most Recent Events
- 18 Jan 2023 Ferring Pharmaceuticals terminates phase II trial in Lactation failure in USA (Intranasal), due to slow recruitment (NCT02545127) (EudraCT2014-000670-20)
- 07 Apr 2021 Chemical structure information added
- 24 Mar 2021 Merotocin - Ferring pharmaceuticals is available for licensing as of 24 Mar 2021. https://www.ferring.com/collaborate/